Abstract:This cohort study assesses the incidence of and risk factors and outcomes associated with breast cancer recurrence of the nipple-areola complex among patients with invasive breast cancer who underwent nipple-sparing mastectomy and immediate breast reconstruction. Key PointsQuestionWhat are the incidence of and risk factors and long-term outcomes associated with breast cancer recurrence at the nipple-areola complex after nipple-sparing mastectomy for invasive breast cancer? FindingsIn this cohort study of 962 breasts from 944 patients who underwent nipple-sparing mastectomy and immediate breast reconstruction for invasive breast cancer, 39 cases of cancer recurrence at the nipple-areola complex were identified as the first event; multifocality or multicentricity, negative hormone receptor and ERBB2 (formerly HER2 or HER2/neu)-positive subtype, high histologic grade, and extensive intraductal component were independently associated with recurrence. Patients with and without recurrence of cancer at the nipple-areola complex as the first event did not differ significantly with regard to distant metastasis-free or overall survival. MeaningThe findings suggest that biological features of the breast cancer tumor should be considered when planning nipple-sparing mastectomy. ImportanceThe main concern associated with nipple-sparing mastectomy (NSM) is the risk of local breast cancer recurrence at the retained nipple-areola complex (NAC) consequent to occult nipple involvement. Long-term follow-up data regarding the oncologic safety of modern therapeutic NSM in terms of cancer recurrence at the NAC and survival are limited. ObjectiveTo assess the incidence, risk factors, treatment, and long-term outcomes associated with cancer recurrence at the NAC in a large series of patients with invasive breast cancer who underwent NSM and immediate breast reconstruction. Design, Setting, and ParticipantsIn this retrospective cohort study at a single institution (Asan Medical Center) in Seoul, Republic of Korea, 962 breasts from 944 patients who underwent NSM and immediate breast reconstruction for invasive breast cancer were analyzed between March 3, 2003, and December 31, 2015. Patients who underwent neoadjuvant systemic therapy or palliative surgery were excluded. Data analysis was performed from June 4, 2018, to August 31, 2018. Main Outcomes and MeasuresUnivariate and multivariate Cox proportional hazards regression models were used to analyze the association between clinicopathologic variables and cancer recurrence at the NAC. To evaluate the association between cancer recurrence at the NAC and prognosis, distant metastasis-free survival, and overall survival were estimated using the Kaplan-Meier method and compared using the log-rank test. ResultsAmong the 944 study patients (median age at diagnosis, 43 years [range, 23-67 years]) during a median follow-up of 85 months (range, 14-185 months), 39 cases (4.1%) of cancer recurrence at the NAC were identified as the first event after NSM. The 5-year cumulative incidence of cancer recurrence at the NAC was 3.5% (n=34). In multivariate analyses, multifocality or multicentricity (hazard ratio [HR], 3.309; 95% CI, 1.501-7.294; P=.003), negative hormone receptor or ERBB2 (formerly HER2 or HER2/neu)-positive subtype (HR, 3.051; 95% CI, 1.194-7.796; P=.02), high histologic grade (HR, 2.641; 95% CI, 1.132-6.160; P=.03), and extensive intraductal component (HR, 3.338; 95% CI, 1.262-8.824; P=.02) were independently associated with cancer recurrence at the NAC after NSM. All 39 recurrent cases involved wide local excision. Patients with and without cancer recurrence at the NAC as the first event did not differ significantly with regard to distant metastasis-free survival (P=.95) or overall survival (P=.21). The 10-year distant metastasis-free survival rates were 89.3% among patients with cancer recurrence at the NAC and 94.3% among patients without recurrence. The 10-year overall survival rates were 100% among patients with cancer recurrence at the NAC and 94.5% among those without recurrence. Conclusions and RelevancePatients had a low incidence of cancer recurrence at the NAC after NSM and immediate breast reconstruction in this study. The findings suggest that multifocal or multicentric disease, hormone receptor-negative/ERBB2-positive subtype, high histologic grade, and positive extensive intraductal component should be considered before determining the NSM procedure.

Oncologic Safety of Nipple-Sparing Mastectomy in Patients with Breast Cancer and Tumor-to-Nipple Distance ≤ 1 cm: A Matched Cohort Study

Nipple-sparing Mastectomy in Breast Cancer: From an Oncologic Safety Perspective

Vascular anatomy and evaluation of the nipple-areola complex in nipple-sparing mastectomies

A Propensity Score-matched Analysis of Long-term Oncologic Outcomes After Nipple-sparing Versus Conventional Mastectomy for Locally Advanced Breast Cancer

Oncologic Outcomes of Nipple-sparing Mastectomy and Immediate Reconstruction After Neoadjuvant Chemotherapy for Breast Cancer

Prediction of nipple involvement in breast cancer after neoadjuvant chemotherapy: Should we rely on breast MRI to preserve the nipple?

Abstract P2-14-13: Propensity Score Matching for Survival Outcomes in Breast Cancer Patients with Nipple Sparing Mastectomy Versus Total Mastectomy and Breast-Conserving Surgery: a Single-Center Retrospective Study

Investigation of the current situation of nipple-sparing mastectomy: a large multicenter study in China (CSBrs-003)

Neoadjuvant chemotherapy as an indication to preserve nipple areolar complex in advanced breast cancer.

Safety of Atypical Ductal Hyperplasia at the Nipple Margin in Nipple-Sparing Mastectomy

Abstract PO4-23-07: Impact of distance between tumor and nipple on locoregional recurrence in breast cancer

Recurrence Outcomes After Nipple-Sparing Mastectomy and Immediate Breast Reconstruction in Patients with Pure Ductal Carcinoma In Situ

Nipple-sparing mastectomy: initial experience at the Memorial Sloan-Kettering Cancer Center and a comprehensive review of literature

Areola Sparing Mastectomy Without Preservation of Nipple: A Clinicopathological Assessment and a Case Series.

Breast Cancer Recurrence in the Nipple-Areola Complex After Nipple-Sparing Mastectomy With Immediate Breast Reconstruction for Invasive Breast Cancer.

Comparison of long-term oncological outcomes after central lumpectomy versus nipple-sparing breast-conserving surgery for centrally located breast cancer: a propensity score-matched study

Long-term Oncologic Outcomes of Immediate Breast Reconstruction vs Conventional Mastectomy Alone for Breast Cancer in the Setting of Neoadjuvant Chemotherapy

Oncological Safety of Skipping Axillary Lymph Node Dissection in Patients with Clinical N0, Sentinel Node-Positive Breast Cancer Undergoing Total Mastectomy

Oncologic Outcomes of Immediate Breast Reconstruction in the Setting of Neoadjuvant Chemotherapy: A Long-term Follow-up Study of a Matched Cohort

Is minimal-accessed (endoscopic- or robotic-assisted) nipple-sparing mastectomy contraindicated for large breasts?

Comparative effectiveness of nipple-sparing mastectomy and breast-conserving surgery on long-term prognosis in breast cancer